Description and Brand Names

Drug information provided by: Merative, Micromedex®

US Brand Name

  1. Lynparza

Descriptions


Olaparib is used as maintenance treatment in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene. Your doctor will test for the presence of this gene. It is used in patients who have received complete or partial treatment with platinum-based cancer medicines.

Olaparib is used together with bevacizumab as maintenance treatment in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of abnormal BRCA gene or a positive tumor test for genomic instability called HRD. Your doctor will test for the presence of this gene. It is used in patients who have received complete or partial treatment with platinum-based cancer medicines.

Olaparib is also used to treat ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has come back. It is used in patients who have received complete or partial treatment with platinum-based cancer medicines.

Olaparib is also used to treat HER2-negative early breast cancer in patients who have been treated with other cancer medicines. It is used if the cancer cells have the germline BRCA mutations. Your doctor will use a special test to look for these mutations. It is given to patients after surgery to remove the tumor.

Olaparib is also used to treat HER2-negative metastatic (cancer that has spread) breast cancer in patients who have been treated with other cancer medicines. It is used if the cancer cells have the germline BRCA mutations. Your doctor will use a special test to look for these mutations.

Olaparib is also used as maintenance treatment in patients with metastatic (cancer that has spread) pancreas cancer with a certain type of inherited (germline) abnormal BRCA gene, whose disease has not progressed and who have been treated with platinum-based cancer medicines for at least 16 weeks.

Olaparib is also used to treat metastatic castration-resistant prostate cancer (prostate cancer that has spread and is resistant to medical or surgical treatments that lower testosterone) in patients who have been treated with other cancer medicines (eg, abiraterone, enzalutamide). It is used if the cancer cells have a certain type of inherited (germline) or acquired (somatic) abnormal HRR gene. Your doctor will test for the presence of this gene.

This medicine is available only with your doctor's prescription.

This product is available in the following dosage forms:

  • Tablet

From Mayo Clinic to your inbox

Sign up for free, and stay up to date on research advancements, health tips and current health topics, like COVID-19, plus expertise on managing health. Click here for an email preview.

To provide you with the most relevant and helpful information, and understand which information is beneficial, we may combine your email and website usage information with other information we have about you. If you are a Mayo Clinic patient, this could include protected health information. If we combine this information with your protected health information, we will treat all of that information as protected health information and will only use or disclose that information as set forth in our notice of privacy practices. You may opt-out of email communications at any time by clicking on the unsubscribe link in the e-mail.

Portions of this document last updated: April 01, 2023

Copyright: © Merative US L.P. 1973, 2023. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.